Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

BACKGROUND: The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib, in combination with endocrine therapy (ET), significantly prolonged progression-free survival in women with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Mukai, Hirofumi, Inoue, Kenichi, Rai, Yoshiaki, Ohno, Shinji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Iwata, Hiroji, Toi, Masakuzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694088/
https://www.ncbi.nlm.nih.gov/pubmed/31127500
http://dx.doi.org/10.1007/s12282-019-00970-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694088/
https://www.ncbi.nlm.nih.gov/pubmed/31127500
http://dx.doi.org/10.1007/s12282-019-00970-7

Ejemplares similares